Immunotherapy in malignant pleural mesothelioma:a long story ended in success  

作　　者：Alberto Bongiovanni Antonio Frassoldati Luana Calabrò 

机构地区：[1]Osteoncology and Rare Tumors Center,IRCCS Istituto Romagnolo per lo Studio dei Tumori(IRST)Dino Amadori,Meldola 47014,Italy [2]Medical Oncology Unit,University Hospital of Ferrara,Ferrara 44121,Italy [3]Medical Oncology Unit,University Hospital of Ferrara,Cona 44124,Italy

出　　处：《Journal of Cancer Metastasis and Treatment》2022年第1期102-113,共12页癌症转移与治疗（英文版）

摘　　要：Malignant pleural mesothelioma(MPM)is an aggressive and rare disease,mainly due to asbestos exposure,characterized by a poor prognosis.For almost two decades,platinum-based chemotherapy has been the only approved therapeutic regimen for first-line MPM,with an overall survival of 12 months.In the last years,the therapeutic scenario of different tumor types,including MPM,has dramatically changed due to immune checkpoint inhibition.The promising results of this approach have promoted new efforts into clinical research,and many trials investigating novel therapeutic combinations are currently ongoing.The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced MPM.

关 键 词：Malignant pleural mesothelioma IMMUNOTHERAPY immune checkpoint inhibitors cancer vaccine 

分 类 号：R734.3[医药卫生—肿瘤]